Jane A Healy

US Patent:

20130059778, Mar 7, 2013

Filed:

Mar 15, 2011

Appl. No.:

13/634935

Inventors:

Vann Bennett - Hillsborough NC, US
Jane Healy - Boston MA, US

International Classification:

C12Q 1/68
C12Q 1/54
G06F 17/30
A61K 38/26
A61K 38/17
A61P 3/10
G01N 33/566
C40B 30/04

US Classification:

514 72, 435 611, 435 792, 435 14, 506 9, 514 69, 707769, 707E17014

Abstract:

Loss of function ankyrin-B variants have impaired function in pancreatic islets and are associated with type 2 diabetes. This finding provides the basis for methods of identifying at-risk individuals for type 2 diabetes and for personalized therapeutic strategies.

US Patent:

20230092707, Mar 23, 2023

Filed:

Mar 4, 2021

Appl. No.:

17/801454

Inventors:

- Rahway NJ, US
Mingmei Cai - Westwood MA, US
Scott J. Diede - New Hope PA, US
Jane Anne Healy - Hoboken NJ, US
Blanca Homet Moreno - Philadelphia PA, US
Nageatte Ibrahim - Plymouth Meeting PA, US
Sybil M.G. Williams - Wayland MA, US

Assignee:

MERCK SHARP & DOHME LLC - Rahway NJ

International Classification:

C07K 16/28
C07K 16/30
A61P 35/00

Abstract:

Provided herein are methods of treating a cancer, an infectious disease or infection, which comprise administering to a subject in need thereof a combination of agents: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; (b) an anti-human CTLA4 antibody or antigen binding fragment thereof; and (c) an anti-human TIGIT antibody or antigen binding fragment thereof. Also provided are therapeutic combinations for use, pharmaceutical compositions and kits containing such agents for the treatment of a cancer, an infectious disease, or an infection.

US Patent:

20210403557, Dec 30, 2021

Filed:

Nov 4, 2019

Appl. No.:

17/288641

Inventors:

Mingmei CAI - Boston MA, US
Elliot K. CHARTASH - Rahway NJ, US
Jane Anne HEALY - Rahway NJ, US
Mallika LALA - Rahway NJ, US
Tommy Ruosi LI - Edison NJ, US
Kapil MAYAWALA - Rahway NJ, US
Raluca Andreia PREDOIU - Kenilworth NJ, US
Sybil M.G. WILLIAMS - Boston MA, US
Zhen ZENG - Westfield NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody.

US Patent:

20210347889, Nov 11, 2021

Filed:

Nov 4, 2019

Appl. No.:

17/289810

Inventors:

- Rahway NJ, US
Elliot K. Chartash - Basking Ridge NJ, US
Kenneth Emancipator - Bernardsville NJ, US
Rosario Garrido - Wayne NJ, US
Jane Anne Healy - Hoboken NJ, US
Jonathan W. Juco - Ridgewood NJ, US
Diane Levitan - Tenafly NJ, US
Qing Zhao - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The present invention relates to dosing regimens of an anti-LAG3 antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an antibody of Lymphocyte-Activation Gene 3 (LAG3). The invention also provides a method for treating cancer in a patient comprising administering to the patient an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is PD-L 1 expression positive, and optionally LAG3 expression positive.

US Patent:

20210317214, Oct 14, 2021

Filed:

Sep 9, 2019

Appl. No.:

17/274531

Inventors:

- Rahway NJ, US
Terrill K. McClanahan - Sunnyvale CA, US
Jane Anne Healy - Hoboken NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07K 16/28
A61P 35/00

Abstract:

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and the use of the combination therapies for the treatment of non-microsatellite instability-high (non-MSI-H) or proficient mismatch repair (pMMR) colorectal cancer.